Eli Lilly Drug Fails to Prevent Alzheimer’s in Study
An experimental drug from
Eli Lilly
LLY 0.61%
& Co. failed to prevent memory loss in a study of healthy older people with a high risk of developing clinical Alzheimer’s disease in one of the first studies aimed at stopping symptoms before they start.
The drug was no better than a placebo over about 4½ years of treatment at slowing patients’ decline in areas including memory and the ability to plan and complete tasks, Lilly said…